Pain Neuromodulation Market to Reach $6.5 Billion by 2030
SAN FRANCISCO, Calif., March 31, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the newsletter Neurotech Business Report, announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, ' The Market for Implanted Pain Neuromodulation Systems: 2025-2030,' the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate. The market includes spinal cord stimulation (SCS) systems as well as peripheral nerve stimulation (PNS) systems. Neurotech Reports estimates that the PNS market will grow at a 29% CAGR between 2025 and 2030.
Major players in the SCS market include Medtronic, Abbott, Boston Scientific, and Nevro, which was recently acquired by medtech manufacturer Globus Medical. The report includes Neurotech Reports editors' analysis of the impact of this transaction on the competitive landscape of the SCS market. Newer players in the SCS market include Saluda Medical, which pioneered the concept of closed-loop SCS, and European firm Biotronik.
Leading competitors in the PNS space include Curonix, which markets an injectable pain stimulator, SPR, which markets a percutaneous system, Nalu Medical, Bioventus, and Mainstay Medical, which markets a restorative neuromodulation system for treatment of back pain of mechanical origin. Several startup and emerging firms are poised to enter the space in coming years.
The Market for Implanted Pain Neuromodulation Systems: 2025-2030 was authored by the editors of Neurotech Reports, including James Cavuoto, Jeremy Koff, Victor Pikov, and others. Now in its 25th year of publishing, Neurotech Reports is the longest-serving publishing and market-intelligence firm serving the neuromodulation market.
The report includes up-to-date information obtained at the 2025 meeting of the North American Neuromodulation Society, the 2025 JP Morgan Healthcare Conference, and other recent events. Data for the report was obtained from dozens of confidential interviews with key executives in the industry as well as numerous implanters of neuromodulation devices.
'There are a number of market research reports that claim to offer insight on the neuromodulation industry. But neuromodulation industry professionals should ask if they've ever seen the authors of those reports at key conferences such as NANS, INS, LSI. Neurotech Reports editors have been covering these events for 25 years and know the key players inside and out,' said James Cavuoto, editor and publisher of Neurotech Reports. 'This report draws on our 25 years of reporting on the neuromodulation industry.'
Image caption: Neurotech Reports recently released its latest forecast on the growth of the market for implanted pain neuromodulation systems, which include spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) systems.
NEWS SOURCE: Neurotech Reports
Keywords: Biotechnology, Neurotech Reports, Market for Implanted Pain Neuromodulation Systems, Neurotech Business Report, Medical technology, biotech, medical devices, neurology, pharmaceuticals, spinal cord stimulation, SAN FRANCISCO, Calif.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
EU Good Food Fruits Add a Fresh Accent to Korea's Culinary Scene
SEOUL, South Korea, Aug. 14, 2025 (GLOBE NEWSWIRE) — EU Good Food has officially introduced premium European kiwis and canned peaches to Korean consumers, marking an important milestone in its collaboration with the Korean market. This launch highlights the initiative's long-term commitment to delivering high-quality, fully traceable European ingredients to Korea's food industry and households. European kiwis and canned peaches, sourced from the Mediterranean region, bring a fresh and flavour-rich dimension to Korean dining. More than just snacks or dessert ingredients, these fruits combine exceptional flavour, texture, and natural balance – making them ideal additions to a wide variety of Korean dishes. A Fresh Accent to Korean Plates Celebrated for their quality and flavour, European kiwis and canned peaches bring a pleasant harmony and creative highlights to Korean cuisine. European kiwis offer a distinctive gentle tartness and naturally active enzymes, making them highly versatile for both sweet and savoury applications. They elevate fruit salads and desserts, while also providing a refreshing counterpoint in traditional dishes. When incorporated into naengmyeon, for instance, the crisp tang of kiwi delivers a clean, invigorating twist that complements the dish's signature flavours. Similarly, European canned peaches offer a mellow sweetness and smooth, velvety texture, making them an ideal ingredient for pancakes, butter tarts, and griddled hotteok. When paired with iced Americano, their rich flavour harmonises with the coffee's bitterness, creating a balanced and indulgent treat. Taste with Integrity – Backed by EU Standards What sets these fruits apart is the assurance of quality under EU Good Food. Cultivated, harvested, and packaged according to strict EU regulations, they are fully traceable from orchard to packaging. European farmers prioritise soil health, minimise synthetic inputs, and protect natural ecosystems. This dedication to quality is evident in each fruit. European kiwis are carefully harvested at peak ripeness. This ensures optimal texture, a balanced sweet-tart flavour, and excellent durability during transport and storage. The result is a fruit that maintains its freshness and appeal long after it leaves the orchard. Similarly, peaches are picked only at full maturity and preserved without unnecessary additives. Thanks to clean, modern processing techniques, canned peaches retain their natural juiciness, aroma, and velvety texture. Beyond flavour and freshness, both kiwis and peaches are naturally rich in vitamin C, potassium, and dietary fibre. Their clean-label profile aligns with Korea's growing demand for minimally processed, additive-free products. The official EU certification ensures that every product meets rigorous safety, quality, and consistency standards. Grown with care and packed with goodness, European kiwis and canned peaches bring freshness, flavour, and essential nutrients to Korean tables. Since its introduction to Korea, the EU Good Food campaign has made a significant impact through a series of targeted and high-profile activities. From immersive tasting events at Seoul Food & Hotel to strategic networking initiatives connecting EU suppliers with Korean buyers – including renowned chefs, importers, and key industry stakeholders – the campaign has actively fostered meaningful exchange and long-term collaboration. It has also showcased how seamlessly European products can be integrated into the Korean culinary landscape. Whether featured in intimate family dinners or innovative fusion menus, these fruits bring a refined and flavourful touch to the season. With their bright and rich taste, European kiwis and canned peaches are a natural choice – equally suited for passionate home cooks looking to elevate everyday meals with superior ingredients, and for culinary professionals aiming to craft truly distinctive dining experiences. About EU Good Food EU Good Food is an EU co-funded initiative dedicated to promoting high-quality, safe, and fully traceable European agricultural products worldwide. Through partnerships with local markets, the campaign connects consumers and industry professionals with certified European ingredients, ensuring taste, transparency, and trust in every product. For more information, please visit: Media contact: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
an hour ago
- Yahoo
European Penny Stocks To Consider In August 2025
Amidst a backdrop of strong corporate earnings and hopes for geopolitical resolutions, the pan-European STOXX Europe 600 Index has seen a notable rise, reflecting investor confidence in the region's market resilience. For investors exploring opportunities beyond well-known names, penny stocks—typically smaller or newer companies—remain an intriguing option. While the term may seem outdated, these stocks can still offer surprising value and potential growth when backed by solid financials. Top 10 Penny Stocks In Europe Name Share Price Market Cap Financial Health Rating Mistral Iberia Real Estate SOCIMI (BME:YMIB) €1.05 €22.87M ★★★★★☆ Maps (BIT:MAPS) €3.34 €44.36M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ Angler Gaming (DB:0QM) €0.37 €299.94M ★★★★★★ Cellularline (BIT:CELL) €3.12 €65.81M ★★★★★☆ Fondia Oyj (HLSE:FONDIA) €4.90 €18.32M ★★★★★★ Bredband2 i Skandinavien (OM:BRE2) SEK3.255 SEK3.12B ★★★★☆☆ ForFarmers (ENXTAM:FFARM) €4.60 €406.57M ★★★★★★ Deceuninck (ENXTBR:DECB) €2.09 €288.55M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.934 €31.5M ★★★★★★ Click here to see the full list of 336 stocks from our European Penny Stocks screener. Let's explore several standout options from the results in the screener. ABIONYX Pharma Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ABIONYX Pharma SA is a biotech company focused on discovering and developing therapies for renal and ophthalmological diseases, with a market cap of €64.01 million. Operations: The company's revenue is primarily derived from its CRO Activity, which generated €4.55 million. Market Cap: €64.01M ABIONYX Pharma, a biotech company with a market cap of €64.01 million, is navigating challenges typical of penny stocks. Despite having more cash than debt and short-term assets exceeding liabilities, it remains pre-revenue with limited cash runway under a year. The company's revenue from CRO activities (€4.55 million) is insufficient to offset its unprofitability, as losses have increased by 18.6% annually over the past five years. While share dilution has been minimal and management is experienced, earnings are forecasted to decline by 33.8% per year for the next three years without expected profitability soon, reflecting high volatility in its stock price. Navigate through the intricacies of ABIONYX Pharma with our comprehensive balance sheet health report here. Gain insights into ABIONYX Pharma's future direction by reviewing our growth report. High Simply Wall St Financial Health Rating: ★★★★★★ Overview: High Co. SA offers consumer engagement chain solutions in France, Belgium, and Spain with a market cap of €91.99 million. Operations: The company generates revenue of €146.38 million from its advertising segment. Market Cap: €92M High Co. SA, with a market cap of €91.99 million, demonstrates financial stability as its short-term assets exceed both short and long-term liabilities, and it has more cash than total debt. Despite high-quality earnings and no significant shareholder dilution recently, the company faces challenges such as negative earnings growth over the past year and declining profit margins. Although its debt is well covered by operating cash flow, the return on equity remains low at 9.7%. Earnings are expected to decline by an average of 13.9% annually over the next three years, indicating potential volatility in stock performance. Take a closer look at High's potential here in our financial health report. Explore High's analyst forecasts in our growth report. Kudelski Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Kudelski SA, along with its subsidiaries, offers digital access and security solutions for digital television and interactive applications across various countries including Switzerland, the United States, France, Germany, and Austria; it has a market cap of CHF81.37 million. Operations: The company's revenue is derived from three main segments: Digital TV, generating $227.83 million; Cybersecurity, contributing $108.47 million; and the Internet of Things, accounting for $47.43 million. Market Cap: CHF81.37M Kudelski SA, with a market cap of CHF81.37 million, is currently unprofitable but offers promising growth prospects in the digital access and security sectors. The company's strategic alliances, such as its partnership with Broadpeak to enhance streaming security for live sports content, highlight its focus on innovation and revenue protection. Despite past losses increasing at 20.3% per year over five years, Kudelski has improved its debt profile significantly from a 117% to 1.9% debt-to-equity ratio and maintains sufficient cash runway for over a year. Its seasoned management team further strengthens its potential for future stability and growth. Click to explore a detailed breakdown of our findings in Kudelski's financial health report. Understand Kudelski's earnings outlook by examining our growth report. Summing It All Up Dive into all 336 of the European Penny Stocks we have identified here. Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:ABNX ENXTPA:HCO and SWX:KUD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
CNBC
an hour ago
- CNBC
CNBC Daily Open: Under Trump, business and politics are becoming bedfellows
Don't mix business with pleasure — or the music of the spheres might eject you from the skies even if you are an astronomer — but it seems, in the current milieu, there are no such restrictions between business and politics. U.S. President Donald Trump's administration is eyeing a stake in struggling chipmaker Intel, according to a Bloomberg report on Thursday. That consideration is primarily attributable to Intel's status as the only born-and-bred American company that can manufacture the fastest chips on U.S. soil. While some firms such as Taiwan Semiconductor Manufacturing Company and Samsung, both of which can produce 3-nanometer chips — the most advanced semiconductors so far — have factories in the U.S., they are Taiwanese and South Korean companies, respectively, and probably do not enjoy apple pies on the Fourth of July. In combination with the news that Nvidia and AMD will pay the U.S. government a 15% share of their revenue from chip sales in China, as well as Apple committing to make more chips in America, the Trump administration seems to be consolidating a chip empire with the White House as its capital. To modify a song last heard by the Astronomer CEO before he was cast down to Earth: "I used to rule the world / Chips would rise when I gave the word."The Trump administration is reportedly considering a stake in Intel. The chipmaker is the only U.S. company that can manufacture the most advanced semiconductors in America. Intel's shares soared 7.4% after Bloomberg reported the news. China's economy falters in July. A series of data released Friday — retail sales, industrial output and fixed-asset investment — all underperformed economists' estimates. The statistics bureau attributed the disappointing performance to extreme weather last month. Berkshire Hathaway unveils a stake in UnitedHealth. Warren Buffett's conglomerate bought more than 5 million shares in the health care firm for a stake worth about $1.6 billion at the end of June, according to a regulatory filing. U.S. stocks flirt with the flatline. The S&P 500's 0.03% gain, however, means it closed at another high on Thursday. Asia-Pacific markets rose Friday. Japan's Nikkei 225 added more than 1% on the country's economy expanding more than expected in the second quarter. [PRO] European defense stocks will benefit from Trump-Putin meeting. Regardless of whether the talks result in any breakthroughs on the war in Ukraine, analysts think it's a "win-win" situation for defense stocks. Germany's Merz strikes sharp tone with Europe as he cozies up to Trump German Chancellor Friedrich Merz is looking to redefine Germany's voice in Europe and build a relationship with U.S. President Donald Trump — whom many of Merz's European colleagues do not see eye to eye with. The historically EU-friendly Merz, a former member of the European Parliament, now has a long list of complaints about the bloc.
